Do analysts recommend BLRX or INKT?

MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 223.77%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MiNK Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00

Do analysts rate BLRX or INCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BLRX or INCR more profitable?

InterCure has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. InterCure's return on equity of 0.00% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% InterCure N/A N/A N/A

Do analysts rate TIL or BLRX?

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 778.83%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TIL or BLRX more profitable?

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% BioLineRx -563.70% -37.73% -19.42%

Do analysts prefer BLRX or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

BioLineRx (BLRX) Competitors

$2.98 +0.07 (+2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.96 -0.02 (-0.67%)

As of 04:10 PM Eastern

Compare

BLRX vs. MREO, INKT, INCR, TIL, and ABVC

Should you buy BioLineRx stock or one of its competitors? MarketBeat compares BioLineRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLineRx include Mereo BioPharma Group (MREO), MiNK Therapeutics (INKT), InterCure (INCR), Instil Bio (TIL), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry.

How does BioLineRx compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

BioLineRx has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	103.05	-$41.88M	-$0.05	N/A
BioLineRx	$1.18M	11.04	-$1.17M	-$1.92	N/A

In the previous week, Mereo BioPharma Group had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Mereo BioPharma Group and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.27 beat Mereo BioPharma Group's score of 0.93 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group	Positive
BioLineRx	Positive

Mereo BioPharma Group has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Mereo BioPharma Group currently has a consensus target price of $3.25, suggesting a potential upside of 906.82%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe Mereo BioPharma Group is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mereo BioPharma Group has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
BioLineRx	-563.70%	-37.73%	-19.42%

Summary

Mereo BioPharma Group beats BioLineRx on 9 of the 15 factors compared between the two stocks.

How does BioLineRx compare to MiNK Therapeutics?

BioLineRx (NASDAQ:BLRX) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

MiNK Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. MiNK Therapeutics' return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
MiNK Therapeutics	N/A	N/A	-118.57%

BioLineRx has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioLineRx has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.04	-$1.17M	-$1.92	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A

MiNK Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 223.77%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, MiNK Therapeutics had 3 more articles in the media than BioLineRx. MarketBeat recorded 4 mentions for MiNK Therapeutics and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.27 beat MiNK Therapeutics' score of 1.24 indicating that BioLineRx is being referred to more favorably in the media.

Company	Overall Sentiment
BioLineRx	Positive
MiNK Therapeutics	Positive

Summary

MiNK Therapeutics beats BioLineRx on 9 of the 15 factors compared between the two stocks.

How does BioLineRx compare to InterCure?

BioLineRx (NASDAQ:BLRX) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioLineRx has higher earnings, but lower revenue than InterCure. BioLineRx is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.04	-$1.17M	-$1.92	N/A
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.10

In the previous week, InterCure had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for InterCure and 1 mentions for BioLineRx. InterCure's average media sentiment score of 1.43 beat BioLineRx's score of 1.27 indicating that InterCure is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLineRx	Positive
InterCure	Positive

InterCure has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. InterCure's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
InterCure	N/A	N/A	N/A

BioLineRx has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, InterCure has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Summary

InterCure beats BioLineRx on 8 of the 12 factors compared between the two stocks.

How does BioLineRx compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 778.83%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Instil Bio has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
BioLineRx	-563.70%	-37.73%	-19.42%

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Instil Bio had 1 more articles in the media than BioLineRx. MarketBeat recorded 2 mentions for Instil Bio and 1 mentions for BioLineRx. Instil Bio's average media sentiment score of 1.74 beat BioLineRx's score of 1.27 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
BioLineRx	Positive

BioLineRx has higher revenue and earnings than Instil Bio. BioLineRx is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
BioLineRx	$1.18M	11.04	-$1.17M	-$1.92	N/A

Summary

Instil Bio beats BioLineRx on 9 of the 14 factors compared between the two stocks.

How does BioLineRx compare to ABVC BioPharma?

BioLineRx (NASDAQ:BLRX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

BioLineRx has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, BioLineRx and BioLineRx both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 1.89 beat BioLineRx's score of 1.27 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLineRx	Positive
ABVC BioPharma	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ABVC BioPharma has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
ABVC BioPharma	N/A	-62.46%	-39.99%

BioLineRx has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.04	-$1.17M	-$1.92	N/A
ABVC BioPharma	$510K	61.69	-$7.91M	-$0.40	N/A

Summary

ABVC BioPharma beats BioLineRx on 6 of the 11 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.71M	$3.02B	$6.85B	$12.45B
Dividend Yield	N/A	2.08%	2.68%	9.43%
P/E Ratio	-1.55	19.86	27.21	24.25
Price / Sales	11.04	486.54	510.37	87.30
Price / Cash	N/A	56.68	48.63	60.03
Price / Book	0.56	4.23	10.78	6.23
Net Income	-$1.17M	$65.46M	$3.59B	$331.94M
7 Day Performance	-1.65%	-3.99%	-2.55%	-1.93%
1 Month Performance	-2.30%	1.63%	2.81%	-0.97%
1 Year Performance	-35.22%	17.90%	25.42%	18.24%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	0.7953 of 5 stars	$2.98 +2.4%	N/A	-35.6%	$12.71M	$1.18M	N/A	40	Positive News Gap Up
MREO Mereo BioPharma Group	2.8136 of 5 stars	$0.33 +5.7%	$3.25 +871.6%	-80.8%	$53.39M	$500K	N/A	40	News Coverage Gap Down
INKT MiNK Therapeutics	3.4034 of 5 stars	$10.62 -8.1%	$35.00 +229.6%	-60.4%	$52.89M	N/A	N/A	30	News Coverage Analyst Upgrade
INCR InterCure	1.363 of 5 stars	$0.96 -3.5%	N/A	-36.2%	$52.76M	$270.20M	32.16	350	Positive News
TIL Instil Bio	1.8346 of 5 stars	$7.75 +0.4%	$66.00 +751.6%	-68.1%	$52.55M	N/A	N/A	410	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. MREO, INKT, INCR, TIL, and ABVC

How does BioLineRx compare to Mereo BioPharma Group?

Summary

How does BioLineRx compare to MiNK Therapeutics?

Summary

How does BioLineRx compare to InterCure?

Summary

How does BioLineRx compare to Instil Bio?

Summary

How does BioLineRx compare to ABVC BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. MREO, INKT, INCR, TIL, and ABVC

How does BioLineRx compare to Mereo BioPharma Group?

Which has better valuation and earnings, MREO or BLRX?

Does the media favor MREO or BLRX?

Which has more volatility and risk, MREO or BLRX?

Do analysts prefer MREO or BLRX?

Do insiders & institutionals hold more shares of MREO or BLRX?

Is MREO or BLRX more profitable?

Summary

How does BioLineRx compare to MiNK Therapeutics?

Is BLRX or INKT more profitable?

Which has more volatility and risk, BLRX or INKT?

Do insiders and institutionals hold more shares of BLRX or INKT?

Which has better valuation & earnings, BLRX or INKT?

Do analysts recommend BLRX or INKT?

Does the media favor BLRX or INKT?

Summary

How does BioLineRx compare to InterCure?

Do institutionals & insiders believe in BLRX or INCR?

Do analysts rate BLRX or INCR?

Which has better earnings and valuation, BLRX or INCR?

Does the media prefer BLRX or INCR?

Is BLRX or INCR more profitable?

Which has more risk and volatility, BLRX or INCR?

Summary

How does BioLineRx compare to Instil Bio?

Do analysts rate TIL or BLRX?

Which has more risk and volatility, TIL or BLRX?

Is TIL or BLRX more profitable?

Do insiders & institutionals hold more shares of TIL or BLRX?

Does the media favor TIL or BLRX?

Which has stronger earnings & valuation, TIL or BLRX?

Summary

How does BioLineRx compare to ABVC BioPharma?

Which has more risk and volatility, BLRX or ABVC?

Does the media prefer BLRX or ABVC?

Do analysts prefer BLRX or ABVC?

Do insiders and institutionals hold more shares of BLRX or ABVC?

Is BLRX or ABVC more profitable?

Which has better earnings and valuation, BLRX or ABVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools